Acadia Insider Sale: CFO Disposes 22,000 Shares Under 10b5-1 Plan
Rhea-AI Filing Summary
Mark C. Schneyer, EVP and Chief Financial Officer of Acadia Pharmaceuticals (ACAD), reported the sale of 22,000 shares of the issuer's common stock on 08/18/2025 at a weighted-average price of $25.1829 per share, with sale prices in the range $25.06 to $25.28. Following the reported disposition, Mr. Schneyer beneficially owned 40,130 shares. The Form 4 discloses the transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 19, 2025. The filing was signed on behalf of the reporting person by an attorney-in-fact on 08/19/2025.
Positive
- Transaction executed under a Rule 10b5-1 plan, indicating pre-planned trades and reduced appearance of opportunistic insider timing
- Filing provides weighted-average price and price range with an undertaking to supply per-price quantities on request, showing transparency
Negative
- Reporting person disposed of 22,000 shares, reducing insider ownership to 40,130 shares which may be viewed negatively by some investors
Insights
TL;DR: Routine officer stock sales under a 10b5-1 plan; not an operational disclosure and likely neutral for ACAD's near-term fundamental outlook.
The Form 4 documents a pre-planned disposition of 22,000 common shares by the CFO executed under a Rule 10b5-1 plan, with a disclosed weighted-average price of $25.1829 and reported price range $25.06 to $25.28. Reporting that the trade was pursuant to a 10b5-1 plan reduces concerns about opportunistic timing, as these plans establish pre-set trading instructions. The filing also shows the reporting person retains 40,130 shares after the sale, which remains a modest ownership position relative to typical executive holdings. This disclosure is procedural and does not present new operational or financial information about Acadia Pharmaceuticals.
TL;DR: Proper disclosure and plan usage indicate governance compliance; the transaction itself is routine and not materially transformative.
The Form 4 explicitly states the trades were covered by a 10b5-1 trading plan adopted May 19, 2025, which provides an affirmative defense against insider trading claims if implemented correctly. The filing includes weighted-average pricing and an undertaking to provide detail on per-price quantities upon request, reflecting transparency. There is no indication of amendments, unusual derivative activity, or changes in officer status in this filing. From a governance perspective, the disclosure aligns with Section 16 reporting requirements and shows procedural compliance.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 22,000 | $25.1829 | $554K |
Footnotes (1)
- The sales reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.06 to $25.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
